早期滤泡性淋巴瘤分期PET/CT具成本效益
研究从加拿大医疗系统视角评估早期滤泡性淋巴瘤(FL)分期PET/CT的成本效益。决策分析模型模拟常规CT分期后加做PET/CT与仅用CT分期的管理,随访30年。结果显示PET/CT策略平均节省终身成本3165加元并增益0.32质量调整生命年(QALY),成为优势策略,建议早期FL患者在根治性放疗前接受PET/CT分期。
要点
- 早期FL患者放疗前加做PET/CT分期可节省成本并提高QALY。
- PET/CT策略在77%模拟中强优势,89%模拟中具成本效益。
- 确定性敏感性分析中PET/CT在所有数据支持场景下均为优选策略。
核心结论
- 早期FL患者根治性放疗前进行PET/CT分期可降低费用并改善QALY,推荐临床采用。
研究设计与样本
- 基于加拿大医疗系统视角的决策分析模型,模拟早期FL患者(常规CT分期后计划根治性放疗)加做PET/CT与仅用CT分期的管理,采用30年时间跨度的状态转移队列模型。
主要发现
- 参考案例中PET/CT为优势策略,平均终身成本节省3165加元并增益0.32 QALY。
- 确定性敏感性分析中PET/CT策略在所有可用数据支持的场景下均为优选策略。
- 概率敏感性分析(10000次模拟)中PET/CT在77%模拟中强优势(降低成本并提高QALY),在89%模拟中具成本效益(节省成本或增量成本效果比低于100000加元/QALY)。
关键数值与推荐
- 意愿支付阈值设为100000加元/QALY。
- 成本和QALY按1.5%贴现率计算。
- 成本以2019年加元计。
临床怎么用
- 早期FL患者在接受根治性放疗前应进行PET/CT分期,以降低费用并改善健康产出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental cost-effectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Patients with early-stage FL should undergo PET/CT before curative-intent RT.
引用
- Lo AC, James LP, Prica A, et al. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma. J Nucl Med. 2021. PMID: 34413148. doi:10.2967/jnumed.121.262324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。